Autolus Therapeutics plc
Autolus Therapeutics plc (AUTL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
autl · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Autolus Therapeutics plc (AUTL) measures how much investors pay for each dollar of the company's trailing earnings. AUTL's current PE ratio of N/A is calculated by dividing its stock price of $1.44 by its TTM earnings per share of -$1.09.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2015 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Autolus Therapeutics plcYou AUTL | $382M | N/A | — | -$1.09 |
 ADC Therapeutics S.A. ADCT | $110M | N/A | — | -$1.12 |
 Annexon, Inc. ANNX | $615M | N/A | — | -$1.33 |
 Aura Biosciences, Inc. AURA | $416M | N/A | — | -$1.76 |
 Benitec Biopharma Inc. BNTC | $276M | N/A | — | -$1.05 |
 LB Pharmaceuticals Inc Common Stock LBRX | $835M | N/A | — | -$1.00 |
 Neumora Therapeutics, Inc. Common Stock NMRA | $299M | N/A | — | -$1.45 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.08 | — | |
2024-12-31 FY2024 | — | $-0.86 | — | |
2023-12-31 FY2023 | — | $-1.20 | — | |
2022-12-31 FY2022 | — | $-1.57 | — | |
2021-12-31 FY2021 | — | $-1.97 | — | |
2020-12-31 FY2020 | — | $-2.76 | — | |
2019-12-31 FY2019 | — | $-2.88 | — | |
2018-09-30 FY2018 | — | $-0.99 | — | |
2017-09-30 FY2017 | — | $-1.43 | — | |
2016-09-30 FY2016 | — | $-0.91 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Autolus Therapeutics plc (AUTL) measures how much investors pay for each dollar of the company's trailing earnings. AUTL's current PE ratio of N/A is calculated by dividing its stock price of $1.44 by its TTM earnings per share of -$1.09.
Frequently asked questions
AUTL pe ratio · 6 questionsAUTL's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.44 and TTM EPS of -$1.09. Data sourced from Financial Modeling Prep via AUTL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Autolus Therapeutics plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08